Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1992 Mar;35(2):83–91. doi: 10.1007/BF01741854

Induction of interleukin-2 receptor by tumor necrosis factor α on cultured ovarian tumor-associated lymphocytes

Constantin G Ioannides 1,✉, Bryan Fisk 1, Barbara Tomasovic 1, Raj Pandita 2, Bharat B Aggarwal 2, Ralph S Freedman 1
PMCID: PMC11038488  PMID: 1534515

Abstract

We have recently reported that autologous tumor-specific cytotoxic T lymphocyte (CTL) lines and clones can be developed from lymphocytes infiltrating ovarian malignant ascites (TAL). In this study, we investigated the biological effects of tumor necrosis factor α (TNFα) in the induction, expansion, long-term proliferation and lytic function of CD8+ TAL. TNFα up-regulated the IL-2 receptor (IL-2R) α chain (Tac antigen) on the surface of CD3+ CD8+ CD4− TAL, enhanced the proliferation of autologous tumor-specific CTL, and potentiated their lytic function in long-term cultures. Furthermore, in the induction and expansion phase of CD8+ TAL, the presence of TNFα was associated with a selective increase in CD8+ IL-2R+ (Tac+) cells, and subsequent decrease in CD4+ IL-2R+ (Tac+) cells. These results suggest that the observed facilitation of the outgrowth of CD8+ cells in TAL cultures may be due, at least in part, to the up-regulation of IL-2R, and indicate the usefulness of TNFα in the analysis of signalling in autologous tumor-reactive CTL.

Key words: TNFα, CD8+ CTL, IL-2R, TIL/TAL

References

  • 1.Aggarwal BB. Human lymphotoxin. Methods Enzymol. 1985;116:441. doi: 10.1016/s0076-6879(85)16035-0. [DOI] [PubMed] [Google Scholar]
  • 2.Barth RJ, Jr, Bock SN, Mulé JJ, Rosenberg SA. Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes. J Immunol. 1990;144:1531. [PubMed] [Google Scholar]
  • 3.Bellegrun A, Kasid A, Uppenkamp M, Topalian SL, Rosenberg SA. Human tumor infiltrating lymphocytres: analysis of lymphokine mRNA expression and relevance to cancer immunotherapy. J Immunol. 1990;142:4520. [PubMed] [Google Scholar]
  • 4.Bringman TS, Aggarwal BB. Monoclonal antibodies to human tumor necrosis factors alpha and beta: application for affinity purification, immunoassays and as structural probes. Hybridoma. 1987;6:489. doi: 10.1089/hyb.1987.6.489. [DOI] [PubMed] [Google Scholar]
  • 5.Depper JM, Leonard WJ, Robb RJ, Waldmann TA, Greene WC. Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of lymphocyte activation. J Immunol. 1983;131:690. [PubMed] [Google Scholar]
  • 6.Fujii M, Sugamura K, Sano K, Nakai M, Sugita K, Hinuma Y. High-affinity receptor-mediated internalization and degradation of interleukin-2 in human T cells. J Exp Med. 1986;163:550. doi: 10.1084/jem.163.3.550. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Ioannides CG, Itoh K, Fox FE, Pahwa R, Good RA, Platsoucas CD. Identification of a second T-cell antigen receptor in human and mouse by an anti-peptide gamma-chain-specific monoclonal antibody. Proc Natl Acad Sci USA. 1987;84:4244. doi: 10.1073/pnas.84.12.4244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Ioannides CG, Freedman RS, Platsoucas CD. OKT4 monoclonal antibody-induced activation of an autoreactive T-cell clone. Cell Immunol. 1989;123:244. doi: 10.1016/0008-8749(89)90284-0. [DOI] [PubMed] [Google Scholar]
  • 9.Ioannides CG, Freedman RS, Liskamp RM, Ward NE, O'Brian CA. Inhibition of IL-2 receptor induction and IL-2 production in the human leukemic cell line Jurkat by a novel peptide inhibitor of protein kinase C. Cell Immunol. 1990;131:242. doi: 10.1016/0008-8749(90)90250-u. [DOI] [PubMed] [Google Scholar]
  • 10.Ioannides CG, Freedman RS, Rashed S, Platsoucas CD, Kim Y-P. Cytotoxic T cell clones isolated from ovarian tumor infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. J Immunol. 1991;146:1700. [PubMed] [Google Scholar]
  • 11.Ioannides CG, Platsoucas CD, Rashed S, Edwards CL, Wharton JT, Freedman RS. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res. 1991;51:4267. [PubMed] [Google Scholar]
  • 12.Itoh K, Platsoucas CD, Balch CM. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. J Exp Med. 1988;168:1419. doi: 10.1084/jem.168.4.1419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Muul LM, Spiess PM, Director EP, Rosenberg SA. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol. 1987;138:989. [PubMed] [Google Scholar]
  • 14.Leonard WJ, Depper JM, Uchiyama T, Smith KA, Waldmann TA, Greene WC. A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor: partial characterization of the receptor. Nature. 1982;300:267. doi: 10.1038/300267a0. [DOI] [PubMed] [Google Scholar]
  • 15.Li YL, Lusheng S, Kanbour A, Herberman RB, Whiteside TL. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor α and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes. Cancer Res. 1989;49:5979. [PubMed] [Google Scholar]
  • 16.Lowenthal JW, Greene WC. Contrasting interleukin 2 binding properties of the α (p55) and β (p70) protein subunits of the human high affinity interleukin 2 receptor. J Exp Med. 1987;166:1156. doi: 10.1084/jem.166.4.1156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Lowenthal JW, Ballard DW, Bohnlein E, Greene WC. Tumor necrosis factor α induces proteins that bind specifically to kB-like enhancer elements and regulate interleukin 2 receptor α chain gene expression in primary human T lymphocytes. Proc Natl Acad Sci USA. 1989;86:2331. doi: 10.1073/pnas.86.7.2331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Robb RJ, Greene WC, Rusk CM. Low and high affinity cellular receptors for interleukin-2: implications for the level of Tac antigen. J Exp Med. 1984;160:1126. doi: 10.1084/jem.160.4.1126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Robinet R, Branellec D, Termijtelen AM, Blay JY, Gay F, Chouaib S. Evidence for tumor necrosis factor-α involvement in the optimal induction of class I allospecific cytotoxic T cells. J Immunol. 1990;144:4555. [PubMed] [Google Scholar]
  • 20.Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233:1318. doi: 10.1126/science.3489291. [DOI] [PubMed] [Google Scholar]
  • 21.Rosenberg SA, Packard BS, Aebersold DM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a primary report. N Engl J Med. 1988;319:1676. doi: 10.1056/NEJM198812223192527. [DOI] [PubMed] [Google Scholar]
  • 22.Schwartzentruber DJ, Topalian SL, Mancini M, Rosenberg SA. Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-α, an IFN-γ by human tumor-infiltrating lymphocytes after autologous tumor stimulation. J Immunol. 1991;146:3674. [PubMed] [Google Scholar]
  • 23.Sharon M, Klausner RD, Cullen BR, Chizzonite R, Leonard WJ. Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions. Science. 1986;234:859. doi: 10.1126/science.3095922. [DOI] [PubMed] [Google Scholar]
  • 24.Smith KA. The interleukin 2 receptor. Adv Immunol. 1988;42:165. doi: 10.1016/s0065-2776(08)60844-5. [DOI] [PubMed] [Google Scholar]
  • 25.Spiess PJ, Yang JC, Rosenberg SA. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst. 1987;79:1067. [PubMed] [Google Scholar]
  • 26.Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA, Shepard HM. Recombinant human tumor necrosis factor-α: effects on proliferation of normal and transformed cells in vitro. Science. 1985;230:943. doi: 10.1126/science.3933111. [DOI] [PubMed] [Google Scholar]
  • 27.Topalian S, Rosenberg SA. Tumor infiltrating lymphocytes. In: Devita V, Hellman S, Rosenberg S, editors. Important advances in oncology 1990. Philadelphia: Lippincott; 1990. pp. 19–41. [PubMed] [Google Scholar]
  • 28.Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol. 1989;142:3714. [PubMed] [Google Scholar]
  • 29.Topalian SL, Kasid A, Rosenberg SA. Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. J Immunol. 1990;144:4487. [PubMed] [Google Scholar]
  • 30.Vaccarello L, Wang Y-L, Whiteside T. Sustained outgrowth of autotumor reactive T lymphocytes from human ovarian carcinomas in the presence of tumor necrosis factor-α and IL-2. Hum Immunol. 1990;28:216. doi: 10.1016/0198-8859(90)90022-h. [DOI] [PubMed] [Google Scholar]
  • 31.Wang HM, Smith KA. The interleukin 2 receptor. Functional consequences of its bimolecular structure. J Exp Med. 1987;1676:1055. doi: 10.1084/jem.166.4.1055. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES